Statement Of Cash Flows

Perseus Proteomics Inc. - Filing #7296856

Concept 2024-04-01 to
2024-09-30
As at
2024-09-30
As at
2024-03-31
2023-04-01 to
2023-09-30
As at
2023-09-30
As at
2023-03-31
Statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-494,203,000 JPY
-632,523,000 JPY
Depreciation
2,577,000 JPY
2,431,000 JPY
Impairment losses
66,959,000 JPY
134,208,000 JPY
Decrease (increase) in trade receivables
5,539,000 JPY
-5,131,000 JPY
Decrease (increase) in inventories
-1,112,000 JPY
114,000 JPY
Subtotal
-310,773,000 JPY
-462,851,000 JPY
Income taxes paid
-1,927,000 JPY
-1,927,000 JPY
Other, net
40,074,000 JPY
-12,308,000 JPY
Net cash provided by (used in) operating activities
-312,460,000 JPY
-464,745,000 JPY
Cash flows from operating activities
Increase (decrease) in accounts payable - other
8,799,000 JPY
-20,502,000 JPY
Cash flows from operating activities
Cash flows from investing activities
Purchase of property, plant and equipment
-52,089,000 JPY
-135,032,000 JPY
Net cash provided by (used in) investing activities
-52,089,000 JPY
-129,402,000 JPY
Cash flows from facilities maintenance and investing activities
Cash flows from financing activities
Net cash provided by (used in) financing activities
919,892,000 JPY
JPY
Effect of exchange rate change on cash and cash equivalents
-10,312,000 JPY
15,222,000 JPY
Net increase (decrease) in cash and cash equivalents
545,029,000 JPY
-578,925,000 JPY
Cash and cash equivalents
2,086,449,000 JPY
1,541,419,000 JPY
1,866,008,000 JPY
2,444,934,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.